GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Longeveron Inc.
Longeveron is a biotech company specializing in cell therapy for aging. Its stock price is a venture bet on a breakthrough in longevity medicine. The chart reflects high volatility and dependence on clinical trial news.
Share prices of companies in the market segment - Stem_cells
Longeveron is a biotech company developing mesenchymal stem cell-based cell therapies for the treatment of age-related diseases and frailty syndromes. We've categorized it under "Stem Cells." The chart below shows how investors view the regenerative medicine sector.
Broad Market Index - GURU.Markets
Longeveron is a biotech company developing stem cell-based therapies for age-related diseases. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Longeveron shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
LGVN - Daily change in the company's share price Longeveron Inc.
For Longeveron Inc., a regenerative medicine company, daily volatility reflects sensitivity to clinical trial data. This metric is key for assessing the risks associated with aging and age-related diseases.
Daily change in the price of a set of shares in a market segment - Stem_cells
Longeveron Inc. is a biotech company. This chart highlights the sector's extreme volatility. Comparison with LGVN, which focuses on cell therapy, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Longeveron is a biotech company working in the fields of regenerative medicine and anti-aging. Its shares are a bet on scientific revolution. Their high volatility, driven by research, is part of the dynamic nature of the innovation sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Longeveron Inc.
For Longeveron Inc., the year-to-date performance is a story about the development of stem cell-based therapies. Its 12-month market cap is entirely dependent on clinical trial data from its drug Lomecel-B, which treats a rare and fatal heart disease in children. Success could be a real breakthrough in regenerative medicine.
Annual dynamics of market capitalization of the market segment - Stem_cells
Longeveron Inc. is a clinical-stage biotechnology company developing stem cell-based therapies for the treatment of aging-related diseases. Its stock price is entirely speculative and based on investor confidence in its breakthrough potential in this complex area of medicine.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Longeveron is a venture bet on one of the most ambitious ideas in medicine: fighting aging with stem cells. Its stock price has nothing to do with economics. It's pure anticipation of a scientific miracle. Any positive signal from the lab could lead to explosive growth, far outpacing the market.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Longeveron Inc.
Longeveron is a clinical-stage biotech company working in cell therapy. Its monthly growth is entirely dependent on the results of its clinical trials for the treatment of aging-related diseases. These trials are the primary catalyst.
Monthly dynamics of market capitalization of the market segment - Stem_cells
Longeveron is a biotech company developing stem cell-based therapies for the treatment of diseases related to aging and inflammation. The chart below shows the overall dynamics of the stem cell sector, one of the most advanced and promising, yet also risky, areas in medicine.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Biotech stocks in the regenerative medicine space are betting on scientific breakthroughs. The chart below shows investors' overall risk appetite. Does Longeveron move in sync with the market, or is its performance driven solely by clinical trial news?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Longeveron Inc.
Longeveron is a biotech company working with stem cells to treat age-related diseases. Its weekly stock price is extremely volatile and directly depends on the publication of clinical trial data. The chart reflects hopes for a breakthrough in longevity medicine.
Weekly dynamics of market capitalization of the market segment - Stem_cells
Biotech stocks like Longeveron often move on clinical trial news. The chart allows us to compare these individual surges with the overall performance of the stem cell sector. Is the weekly rise or fall the result of a unique event or a broader market trend?
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Longeveron, a biotech company specializing in cellular medicine, lives in a world of clinical trial news. This chart is a great way to see how its weekly fluctuations are detached from overall market trends. Is it ignoring macroeconomic noise while pursuing its scientific trajectory?
Market capitalization of the company, segment and market as a whole
LGVN - Market capitalization of the company Longeveron Inc.
The Longeveron Inc. chart is a pure visualization of biotech hopes. Its market cap doesn't reflect revenue, but rather investors' bets on the success of cell therapy for age-related diseases. Every peak and trough on the chart represents the market's reaction to news of clinical trials.
LGVN - Share of the company's market capitalization Longeveron Inc. within the market segment - Stem_cells
Longeveron is a biotech company developing stem cell-based therapies for the treatment of age-related diseases and chronic conditions. In the cutting-edge stem cell segment, its market capitalization reflects investors' faith in the potential of regenerative medicine. The company's market capitalization reflects the success of its clinical trials.
Market capitalization of the market segment - Stem_cells
Longeveron is at the forefront of regenerative medicine, fighting aging. How big is this "eternal youth" industry? The chart below is a barometer of the entire stem cell sector. Its extreme volatility reflects both the enormous promise of breakthroughs and the high risks inherent in this futuristic field.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Longeveron chart is a visualization of the hope for extended healthy life. The valuation of this biotech company, which uses stem cells to treat age-related diseases, is a pure venture bet. Every bounce in the chart is the market's reaction to clinical trial data, which could either create a miracle or destroy everything.
Book value capitalization of the company, segment and market as a whole
LGVN - Book value capitalization of the company Longeveron Inc.
For Longeveron, a company focused on cell therapy for age-related diseases, book value is its physical foundation: laboratories, stem cell processing facilities, and financial reserves. The chart below shows how the company built this physical foundation for its cutting-edge research.
LGVN - Share of the company's book capitalization Longeveron Inc. within the market segment - Stem_cells
Longeveron operates at the forefront of regenerative medicine. Its key assets are state-of-the-art laboratories and manufacturing facilities (GMP) for stem cell processing and storage. These sterile facilities are a physical incubator for the drugs of the future. The chart shows the company's control over this unique cell infrastructure.
Market segment balance sheet capitalization - Stem_cells
Longeveron is a cell therapy company. Pharmaceuticals, as the chart shows, are capital-intensive. Longeveron is a prime example. Its business requires the construction of its own highly complex and expensive laboratories and factories to produce cell therapy products.
Book value of all companies included in the broad market index - GURU.Markets
Longeveron's book value is derived not from its factories, but from its cutting-edge laboratories and capital invested in clinical research in regenerative medicine using stem cells. Its assets reflect its scientific foundation and financial "headroom" for developing future therapies. The chart illustrates its scale.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Longeveron Inc.
Longeveron is a biotech company working with stem cells to treat diseases associated with aging. Its balance sheet is cash for research. Its market capitalization reflects investors' pure faith in the breakthrough potential of its cell therapy, Lomecel-B. The chart reflects the high hopes and risks associated with this cutting-edge field of regenerative medicine.
Market to book capitalization ratio in a market segment - Stem_cells
Longeveron is a biotech company developing cell therapies to treat age-related diseases. Its value is almost entirely dependent on the success of clinical trials. The chart shows the high market valuation of its scientific potential and future drugs compared to its minimal tangible assets.
Market to book capitalization ratio for the market as a whole
Longeveron is a biotech company working with stem cells. Its market valuation is based on the potential of future drugs and patents, not the value of lab equipment. This chart illustrates how investor expectations for breakthrough medical technologies exceed the average market valuation of tangible assets.
Debts of the company, segment and market as a whole
LGVN - Company debts Longeveron Inc.
Longeveron is a clinical-stage biotech company developing cell therapies for age-related diseases. Without sales revenue, it relies entirely on external capital. Debt instruments can be used to finance expensive and lengthy clinical trials, allowing it to advance its research toward potential regulatory approval.
Market segment debts - Stem_cells
Longeveron is a clinical-stage biotech company working in the fields of regenerative medicine and stem cells. For such companies, a lack of revenue and reliance on equity capital to fund lengthy and expensive clinical trials is the norm. This chart reflects its financial position and the "headroom" for continuing research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Longeveron Inc.
Longeveron is a biotech company working with cell technologies. This chart shows its financial structure. For a company in clinical development, without stable sales revenue, any level of debt is an extreme risk. Its survival depends on successful trials and raising equity capital, not on its ability to service its debt.
Market segment debt to market segment book capitalization - Stem_cells
Longeveron is a biotech company developing stem cell-based therapies to treat age-related diseases. This is a cutting-edge, but highly capital-intensive, field. The chart shows the overall debt burden in the sector, giving investors insight into how Longeveron finances its lengthy and expensive clinical trials.
Debt to book value of all companies in the market
Longeveron is a biotech company developing cell therapies to treat age-related diseases. Being in clinical trials, it relies not on debt but on investors' faith in its science. This chart, reflecting the debt burden of a mature economy, highlights that Longeveron's capital is a risky investment in the future, not a loan secured by assets.
P/E of the company, segment and market as a whole
P/E - Longeveron Inc.
For Longeveron, a clinical-stage biotech, the classic P/E ratio isn't applicable because it's non-profitable. Its valuation on this chart is arbitrary. Its true value is determined by investors' faith in its scientific platform for combating aging and the potential of future cell therapies.
P/E of the market segment - Stem_cells
Longeveron is a clinical-stage biotech company developing stem cell-based therapies to treat diseases related to aging and inflammation. This chart shows the average valuation for the sector, providing investors with context for evaluating this cutting-edge, yet risky, field of medicine.
P/E of the market as a whole
Longeveron is a biotech company developing stem cell-based therapies for the treatment of aging-related diseases. Its valuation is a pure bet on the success of its research and is unrelated to the general economic cycles illustrated by this chart. Its fate is decided in clinics and the minds of regulators, not on the stock market.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Longeveron Inc.
Longeveron is a clinical-stage biotech company developing stem cell-based therapies for age-related diseases. This chart reflects investors' long-term expectations for clinical trial results. The company's valuation is based on the potential of its regenerative medicine platform.
%20P%2FE%20Longeveron%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Longeveron-Inc.&v=1772643453367 "Chart of the company's future (projected) P/E Longeveron Inc.")
Future (projected) P/E of the market segment - Stem_cells
Longeveron is a biotech company focused on regenerative medicine and cell therapy for age-related diseases. Its valuation, relative to other biotechs, reflects investors' confidence in the potential of its Lomecel-B platform. This is a speculative bet that its developments will lead to a breakthrough in the treatment of complex conditions.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Stem_cells&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Stem_cells&v=1772643453377 "Future (projected) P/E graph of the market segment - Stem_cells")
Future (projected) P/E of the market as a whole
Longeveron is a biotech company specializing in cell therapy for age-related diseases. Its valuation depends entirely on the success of clinical trials and investor confidence in the potential of its developments. This chart shows the overall investor risk appetite, which is critical for funding long-term, high-risk biotech projects.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772643453392 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Longeveron Inc.
Longeveron is a clinical-stage biotech company developing cell therapies for age-related diseases. The financial performance presented here primarily reflects the costs of conducting expensive clinical trials. The company's future success is entirely dependent on positive results and regulatory approval.
Profit of companies in the market segment - Stem_cells
Longeveron is a biotech company developing cell therapies to treat age-related diseases. It's at the cutting edge of medicine. This chart shows the overall profitability (or loss) of the stem cell sector. It helps us understand whether this innovative industry is on track for commercial success or still requires massive R&D investment.
Overall market profit
Longeveron is a biotech company researching cell therapies for age-related diseases. Its future depends entirely on successful clinical trials and regulatory approval, not economic cycles. This chart shows the state of the economy, which affects LGVN's capital availability but not its scientific work.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Longeveron Inc.
Longeveron is a biotech company specializing in cell therapy for age-related diseases. Its future profit forecast is entirely dependent on clinical trial results and regulatory approval. This chart shows analysts' confidence in the scientific and commercial potential of its regenerative medicine developments.
%20profit%20of%20the%20company%20Longeveron%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Longeveron-Inc.&v=1772643453423 "Graph of future (projected) profit of the company Longeveron Inc.")
Future (predicted) profit of companies in the market segment - Stem_cells
Longeveron is a clinical-stage biotech company developing cell therapies for age-related diseases. This chart shows profit projections for the entire stem cell sector. It illustrates the enormous hopes and high risks of an industry where the success of a single company like Longeveron depends solely on positive clinical trial results.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Stem_cells&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Stem_cells&v=1772643453429 "Graph of future (predicted) profits of companies in a market segment - Stem_cells")
Future (predicted) profit of the market as a whole
This reflects market profit forecasts, which impact venture capital. For Longeveron, a cell therapy company, access to funding is critical for its expensive research. An optimistic forecast increases investors' risk appetite, while pessimism can choke cash flow in biotech.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772643453444 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Longeveron Inc.
Longeveron is a biotech company developing cell therapies. With virtually zero revenue, this figure is a pure reflection of hope. It demonstrates the enormous value the market is placing on the potential future sales of its drugs, should they prove successful.
P/S market segment - Stem_cells
Longeveron is a biotech company developing cell therapies for the treatment of age-related diseases and chronic conditions. This chart shows the average valuation in the stem cell sector. It reflects investor confidence in the potential of regenerative medicine and allows one to assess how Longeveron's prospects fit into overall industry expectations.
P/S of the market as a whole
Longeveron Inc. is a clinical-stage biotech company developing cell therapies for age-related diseases. The company's valuation is based on expected future revenue from its developments. This chart, reflecting how the market values existing revenue, clearly demonstrates the speculative nature of investing in breakthrough medicine.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Longeveron Inc.
Longeveron is a biotech company developing cell therapies for age-related diseases. Its value is determined almost entirely by expectations of future commercial success. This chart reflects investors' confidence that its drugs will pass clinical trials and generate significant revenue in the future.
%20P%2FS%20Longeveron%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Longeveron-Inc.&v=1772643453526 "The graph of the company's future (projected) P/S Longeveron Inc.")
Future (projected) P/S of the market segment - Stem_cells
Longeveron is a biotech company specializing in cell therapy for diseases related to aging and inflammation. Its lead candidate targets frailty syndrome. This chart shows how investors assess the commercial potential of its stem cell-based developments compared to other biotech companies.
%20P%2FS%20market%20segment%20graph%20-%20Stem_cells&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Stem_cells&v=1772643453534 "Future (projected) P/S market segment graph - Stem_cells")
Future (projected) P/S of the market as a whole
This chart shows investors' overall risk appetite and confidence in future growth. For Longeveron, a clinical-stage biotech company working with stem cells, this is an indicator of capital availability. Market optimism creates a favorable environment for funding the lengthy and costly research on which the company's future depends.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772643453549 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Longeveron Inc.
Longeveron is a biotech company developing mesenchymal stem cell-based therapies for the treatment of diseases associated with aging and inflammation. This chart reflects revenue from grants and clinical trials. In the future, it will show revenue from sales of drugs for the treatment of frailty and hypoplastic left heart disease.
Sales of companies in the market segment - Stem_cells
Longeveron is a biotech company developing cell therapies to combat age-related diseases. This chart reflects financial activity in the regenerative medicine sector. Longeveron's progress in clinical trials is an important part of the overall picture, demonstrating the potential of stem cells to create breakthrough treatments.
Overall market sales
Longeveron Inc. is a biotech company developing cell therapies for age-related diseases. Its growth depends on research funding. The overall economic environment, shown in this chart, influences investors' risk appetite and their willingness to invest in long-term, capital-intensive research projects.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Longeveron Inc.
Longeveron is a biotech company specializing in cell therapy for age-related diseases and chronic conditions. Its future revenue depends on the results of clinical trials and regulatory approval of its stem cell-based therapies. This chart represents analysts' assessment of the scientific potential and commercial prospects of the company's developments.
%20sales%20of%20the%20company%20Longeveron%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Longeveron-Inc.&v=1772643453614 "Schedule of future (projected) sales of the company Longeveron Inc.")
Future (projected) sales of companies in the market segment - Stem_cells
Longeveron is a biotech company developing stem cell-based therapies for age-related diseases. This chart illustrates analyst sentiment regarding the entire regenerative medicine sector. It provides insight into the growth potential of this cutting-edge field, where Longeveron is seeking to carve out a niche.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Stem_cells&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Stem_cells&v=1772643453657 "Schedule of future (projected) sales of companies in the market segment - Stem_cells")
Future (projected) sales of the market as a whole
Longeveron Inc. is a clinical-stage biotech company specializing in cell therapy for age-related diseases. Its growth depends on research funding. The overall economic environment, reflected in this chart, influences investor risk appetite, which is critical for raising capital for long-term, research-intensive projects.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772643453678 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Longeveron Inc.
Longeveron is a biotech company developing cell therapies to treat age-related diseases. This chart shows the financial picture at the active research stage. Negative values represent investments in expensive clinical trials, the success of which determines the company's future ability to monetize its scientific breakthroughs.
Market segment marginality - Stem_cells
Longeveron is a biotech company developing stem cell-based therapies to combat aging. For a company in the research stage, this chart serves as a benchmark. It shows the average profitability in their sector, illustrating the potential profitability the company aspires to achieve if its drugs are commercially successful.
Market marginality as a whole
Longeveron is a biotech company developing cell therapies for aging-related diseases. This overall market return curve influences the biotech investment climate. Longeveron's success depends on scientific breakthroughs rather than economics, but overall market stability determines investor willingness to fund long and risky clinical trials.
Employees in the company, segment and market as a whole
Number of employees in the company Longeveron Inc.
Longeveron is a biotech company developing cell therapies for age-related diseases. The chart shows a small but highly qualified team of scientists and clinicians. Their number reflects the current phase of clinical trials, where expertise is more important than scale.
Share of the company's employees Longeveron Inc. within the market segment - Stem_cells
Longeveron is at the forefront of regenerative medicine, developing stem cell-based therapies. In this knowledge-intensive field, the team is the most important asset. This chart shows the percentage of leading scientists and clinicians in this narrow and promising field of biotechnology the company attracts, reflecting its concentration of unique intellectual capital.
Number of employees in the market segment - Stem_cells
Longeveron is a biotech company developing stem cell-based therapies for the treatment of age-related and rare diseases. It is at the forefront of regenerative medicine. This graph illustrates how science-intensive this sector is, requiring the involvement of elite biologists capable of working with living cells to create the drugs of the future.
Number of employees in the market as a whole
Longeveron operates in the cutting-edge stem cell sector, which requires the highest levels of skill. This graph illustrates the overall scale of the labor market, but its quality is determined specifically by these knowledge-intensive companies. Their demand for scientists and researchers creates high-paying jobs, driving the knowledge economy forward and setting trends for the entire industry.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Longeveron Inc. (LGVN)
Longeveron is a biotech company working in cell therapy and regenerative medicine. This chart is a classic example of valuing intellectual capital. The company has no mass production; its value is based on the expectations of its therapeutic platform (LOMEC). The chart shows how highly the market values this scientific potential per scientist.
%20of%20the%20company%20Longeveron%20Inc.%20(LGVN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Longeveron-Inc.-LGVN&v=1772643453925 "Chart of market capitalization per employee (in thousands of dollars) of the company Longeveron Inc. (LGVN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Stem_cells
Longeveron operates at the forefront of medicine, developing stem cell-based treatments. In biotech, market capitalization often reflects not current revenues but the potential of the intellectual property created by a small team of scientists. This chart shows this market premium per employee, comparing it to other innovators in the sector. It's an assessment of investors' faith in future success.
%20by%20market%20segment%20-%20Stem_cells&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Stem_cells&v=1772643453928 "Market capitalization per employee (in thousands of dollars) by market segment - Stem_cells")
Market capitalization per employee (in thousands of dollars) for the overall market
Longeveron Inc. is a biotech company developing stem cell-based therapies. This chart shows the average market value assigned to each employee. For a research-intensive company, this is a way to assess the market premium placed on the potential of breakthrough medical technologies.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772643453932 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Longeveron Inc. (LGVN)
Longeveron is a clinical-stage biotech company working with stem cells. The company has no commercial products. This chart shows the net loss per employee. It reflects not inefficiency, but the company's "bet"—how much it invests in each scientist to conduct research and develop breakthrough therapies.
%20Chart%20Longeveron%20Inc.%20(LGVN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Longeveron-Inc.-LGVN&v=1772643453957 "Company Profit Per Employee (in thousands of dollars) Chart Longeveron Inc. (LGVN)")
Profit per employee (in thousands of dollars) in the market segment - Stem_cells
Longeveron is a biotech company developing cell therapies for age-related diseases. Its business is built on lengthy and expensive research, where highly qualified scientists play a key role. The data in this chart demonstrates how effectively the company manages its intellectual capital, translating scientific research into commercial potential per employee.
%20in%20the%20market%20segment%20-%20Stem_cells&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Stem_cells&v=1772643453958 "Chart of profit per employee (in thousands of dollars) in the market segment - Stem_cells")
Profit per employee (in thousands of dollars) for the market as a whole
Longeveron (LGVN) is a clinical-stage biotech company working with stem cell therapies to treat aging and rare diseases. It's a pure R&D operation. This chart shows the average profitability per employee across the market. For LGVN (which is currently losing money), this is a benchmark: in biotech, a small team of scientists can create a product that will significantly exceed this average in the future.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772643453973 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Longeveron Inc. (LGVN)
Longeveron is a clinical-stage biotech company working with cell therapy. For such a company, this chart is primarily a starting point. Current metrics may be zero, but they serve as a starting point for assessing future commercial potential once their innovative treatments reach the market.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Longeveron-Inc.-LGVN&v=1772643453991 "Sales chart per company employee Longeveron Inc. (LGVN)")
Sales per employee in the market segment - Stem_cells
Longeveron is a biotech company researching stem cell therapies for age-related diseases. Revenue is often absent during the R&D phase. This chart shows the average revenue per employee in this segment, setting a productivity benchmark for commercial biotech companies. It helps evaluate the effectiveness of LGVN's staff within the context of the entire industry.
Sales per employee for the market as a whole
Longeveron is a clinical-stage biotech company developing cell therapies for age-related diseases. The company currently has no approved products or commercial revenue. This metric doesn't reflect its value, as its entire team of scientists and doctors is focused on R&D, not sales.
Short shares by company, segment and market as a whole
Shares shorted by company Longeveron Inc. (LGVN)
Longeveron is a biotech company betting on regenerative medicine, using stem cells to treat age-related diseases, including fragility syndrome. This is a highly speculative and expensive science. This chart shows the number of investors betting the company will run out of money before its therapy proves effective.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Longeveron-Inc.-LGVN&v=1772643454073 "Short Shares Chart for the Company Longeveron Inc. (LGVN)")
Shares shorted by market segment - Stem_cells
Longeveron Inc. is a biotech company researching stem cell-based therapies for age-related diseases, including frailty syndrome. It's a highly risky business. This chart reflects the total short position in the cell therapy sector. High values indicate general investor skepticism about the safety, efficacy, or commercialization of these complex treatments.
Shares shorted by the overall market
Longeveron is a biotech company researching aging and rare diseases using stem cells. It's a very "long-term" science. This chart illustrates the overall market pessimism. When investors are fearful, they're unwilling to fund R&D that might yield results in 10-15 years. They sell their "dreams" and cash in.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Longeveron Inc. (LGVN)
This chart shows the high volatility of Longeveron. The company is developing cell therapy (stem cells) for age-related diseases, including frailty syndrome and Alzheimer's. Positive data from early-phase trials is driving euphoria and "overheating" (above 70). The high risk of failure in later phases and the need for capital are leading to "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Longeveron-Inc.-LGVN&v=1772643454125 "RSI 14 indicator chart for the company's stock Longeveron Inc. (LGVN)")
RSI 14 Market Segment - Stem_cells
Longeveron (LGVN) is a "biotech" that fights *aging*. Their "thing" is *stem cells* (LMSCs) for the treatment of *age-related* diseases (senile asthenia syndrome, Alzheimer's). The "Stem_cells" (biotech) sector is riding the hype. RSI_14_Seg shows the "temperature" of *the entire* segment. It helps us understand: is LGVN's growth due to their R&D, or is *the entire* biotech sector "overheated"?
RSI 14 for the overall market
Longeveron (LGVN) is a biotech company. Like everything in its sector, it's critically dependent on this curve. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast LGVN (Longeveron Inc.)
Longeveron (LGVN) is a biotech company developing mesenchymal stem cell (LSC)-based cell therapies for the treatment of aging and rare diseases. This chart shows the average target price. It reflects analysts' speculative valuation of this regenerative platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-LGVN-Longeveron-Inc.&v=1772643454146 "A chart showing analyst consensus forecasts for the expected stock price. LGVN (Longeveron Inc.)")
The difference between the consensus estimate and the actual stock price LGVN (Longeveron Inc.)
Longeveron is a biotech company developing a stem cell-based therapy (Lomecel-B) for diseases related to aging and inflammation. This chart shows the difference between the market valuation and the consensus forecast. It reveals whether experts believe in this complex but promising regenerative medicine.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-LGVN-Longeveron-Inc.&v=1772643454176 "A chart showing the difference between the consensus forecast and the actual stock price. LGVN (Longeveron Inc.)")
Analyst consensus forecast for stock prices by market segment - Stem_cells
Longeveron is a biotech company attempting to "cure" aging. The company is developing stem cell therapy to combat age-related frailty and Alzheimer's disease. This chart reflects general expectations for the stem cell sector, showing whether experts believe in a breakthrough in anti-aging R&D.
Analysts' consensus forecast for the overall market share price
Longeveron is a biotech company specializing in cell therapy (stem cells) for the treatment of aging-related diseases (Alzheimer's, frailty). This chart shows the overall market appetite. For Longeveron, which operates in the speculative longevity space, overall market optimism (the rising chart) is critical for R&D funding.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Longeveron Inc.
Longeveron is an R&D company working at the cutting edge of medicine: stem cells. Their R&D platform (LOMECEL-B) uses stem cells from young donors to treat age-related diseases (Alzheimer's, frailty). This graph is a clear indicator of faith in their (very risky) science. It reflects their progress in clinical trials and their speculative potential.
AKIMA Market Segment Index - Stem_cells
Longeveron (LGVN) is a biotech company specializing in cell therapy. They use mesenchymal stem cells (LMSCs) from young, healthy donors to treat diseases related to aging and inflammation. The chart shows the segment's average index, helping investors assess how this anti-aging therapy compares to the market average.
The AKIM Index for the overall market
Longeveron is a biotech company developing a cell therapy (Lomecel-B) for the treatment of aging and life-threatening conditions (hypoplastic left heart syndrome). This chart, which reflects the market average, is an indicator of risk appetite. It shows the macro backdrop important for this regenerative medicine.
